CCG-1423
CCG-1423 is a potent small molecule inhibitor that selectively targets the RhoA signaling pathway, thereby inhibiting Serum Response Factor (SRF) -mediated gene transcription. It is a valuable research tool for studying Rho GTPase pathways in cellular models of fibrosis, cancer metastasis, and cardiovascular function, with demonstrated utility in both in vitro and in vivo experimental systems.
Product Specifications
CAS Number
285986-88-1
Product Name Alternative
Bioisostere, Apoptosis, conformational restriction, CCG 1423, CCG1423, CCG-1423, glucose tolerance, G2019S LRRK2, Inhibitor, LRRK2 (WT), metastasis, PC-3, mice, inhibit, Ras, prostate, serum, RhoA
Field of Research
Cell Biology, Pharmacology & Drug Discovery, Signal Transduction
Purity
99.63% (May vary between batches)
Solubility
10% DMSO+40% PEG300+5% Tween 80+45% Saline:3.3 mg/mL (7.26 mM) ; DMSO:245 mg/mL (538.76 mM) ; H2O:< 1 mg/mL (insoluble or slightly soluble) ; Ethanol:4 mg/mL (8.8 mM)
Smiles
CC (ONC (=O) c1cc (cc (c1) C (F) (F) F) C (F) (F) F) C (=O) Nc1ccc (Cl) cc1
Molecular Formula
C18H13ClF6N2O3
Molecular Weight
454.75
Storage Conditions
-20°C
Notes
For research use only.
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
orb2693145-01 5 mg
Cys-Gly-His-Gly-Asn-Lys-Ser-Amyloid β -Protein (33-40)
Sign In for Pricing
View Details orb2693145-02 10 mg
Cys-Gly-His-Gly-Asn-Lys-Ser-Amyloid β -Protein (33-40)
Sign In for Pricing
View Details 
B2852-41A 100 µg
BAZ2B (Bromodomain Adjacent to Zinc Finger Domain Protein 2B, hWALp4, KIAA1476)
Sign In for Pricing
View Details